Drugs / Trifluridine/Tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05077839 | Sep 2021 → Aug 2024 | colorectal cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05077839 ↗ |
| Route | Oral | “35mg/m2 orally taken on d1-5 and d8-12” NCT05077839 ↗ |